Chugai Pharmaceutical Co (STU:CUP) Cyclically Adjusted Revenue per Share: €3.35 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CUP Chugai Pharmaceutical Co Ltd STU:CUP
95 GF Score
Price €36.79
GF Value €42.02
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Chugai Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Chugai Pharmaceutical Co STU:CUP -5.35% 95 Cyclically Adjusted Revenue per Share is €3.35 as of Jun. 2026. GuruFocus rates STU:CUP with a GF Score™ of 95/100 and a GF Value™ of €42.02 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Chugai Pharmaceutical Co's adjusted revenue per share for the three months ended in Jun. 2026 was €1.121. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €3.35 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Chugai Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 10.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 13.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Chugai Pharmaceutical Co was 14.00% per year. The lowest was 5.10% per year. And the median was 11.70% per year.

As of today (2026-08-01), Chugai Pharmaceutical Co's current stock price is €36.79. Chugai Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €3.35. Chugai Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 10.98.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Chugai Pharmaceutical Co was 18.92. The lowest was 5.02. And the median was 10.90.


Chugai Pharmaceutical Co  (STU:CUP) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Chugai Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=36.79/3.35
=10.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Chugai Pharmaceutical Co was 18.92. The lowest was 5.02. And the median was 10.90.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Chugai Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Chugai Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Chugai Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chugai Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.74 2.98 3.01 3.21 3.18

Chugai Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.25 3.25 3.18 3.34 3.35

STU:CUP vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chugai Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


STU:CUP
95GF Score
Chugai Pharmaceutical Co Ltd STU:CUP
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chugai Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Chugai Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.121/113.6000*113.6000
=1.121

Current CPI (Jun. 2026) = 113.6000.

Chugai Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.608 98.000 0.705
201612 0.649 98.400 0.749
201703 0.633 98.100 0.733
201706 0.622 98.500 0.717
201709 0.622 98.800 0.715
201712 0.667 99.400 0.762
201803 0.686 99.200 0.786
201806 0.652 99.200 0.747
201809 0.657 99.900 0.747
201812 0.730 99.700 0.832
201903 0.747 99.700 0.851
201906 0.827 99.800 0.941
201909 0.968 100.100 1.099
201912 0.890 100.500 1.006
202003 0.917 100.300 1.039
202006 0.947 99.900 1.077
202009 1.019 99.900 1.159
202012 1.013 99.300 1.159
202103 0.793 99.900 0.902
202106 1.014 99.500 1.158
202109 1.347 100.100 1.529
202112 1.523 100.100 1.728
202203 1.677 101.100 1.884
202206 1.011 101.800 1.128
202209 0.965 103.100 1.063
202212 1.863 104.100 2.033
202303 1.326 104.400 1.443
202306 1.040 105.200 1.123
202309 0.993 106.200 1.062
202312 1.060 106.800 1.127
202403 0.884 107.200 0.937
202406 1.107 108.200 1.162
202409 1.209 108.900 1.261
202412 1.140 110.700 1.170
202503 1.088 111.100 1.112
202506 1.057 111.700 1.075
202509 1.167 112.000 1.184
202512 1.153 113.000 1.159
202603 1.066 112.700 1.075
202606 1.121 113.600 1.121

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €3.35 mean?
Chugai Pharmaceutical Co (STU:CUP) has a Cyclically Adjusted Revenue per Share of €3.35 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Chugai Pharmaceutical Co and its competitors.
Is Chugai Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Chugai Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is €3.35. Overall, Chugai Pharmaceutical Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
Chugai Pharmaceutical Co's Cyclically Adjusted Revenue per Share of €3.35 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Chugai Pharmaceutical Co and its competitors. Chugai Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is €3.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (STU:CUP) is currently considered Modestly Undervalued. The stock's GF Value™ is €42.02, compared to a current price of €36.79 — trading 12.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €3.35. Chugai Pharmaceutical Co's overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Chugai Pharmaceutical Co (STU:CUP), the current Cyclically Adjusted Revenue per Share is €3.35 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chugai Pharmaceutical Co (STU:CUP) Overvalued in 2026?

Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued. The current stock price of €36.79 is trading 12.4% below its estimated GF Value™ of €42.02. GuruFocus considers Chugai Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for STU:CUP:

  • Cyclically Adjusted Revenue per Share: €3.35
  • GF Value™: €42.02 vs. price of €36.79 (12.4% below fair value)
  • GF Score™: 95/100 with 1 warning sign

No single metric tells the full story. See the STU:CUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chugai Pharmaceutical Co Business Description

Address 2-1-1 Muromachi, Nihonbashi, 12th Floor, Nihonbashi Mitsui Tower, Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
95GF Score

Get the complete analysis for STU:CUP

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€36.79
Price
€42.02
GF Value